Connor Clark & Lunn Investment Management Ltd. Has $6.33 Million Stock Holdings in GoodRx Holdings, Inc. (NASDAQ:GDRX)

Key Points

• Connor Clark & Lunn Investment Management Ltd. increased its stake in GoodRx Holdings, Inc. by 16.7%, now holding 1,434,625 shares valued at approximately $6.3 million.
• Multiple analysts have downgraded GoodRx's stock price targets, with Wells Fargo lowering theirs from $8.00 to $7.00, while UBS and Goldman Sachs reduced theirs to $5.25 and $5.00, respectively.
• In its latest earnings report, GoodRx missed earnings expectations by $0.01, reporting an EPS of $0.09 and revenue of $203.07 million, slightly below analyst forecasts.

Connor Clark & Lunn Investment Management Ltd. raised its holdings in shares of GoodRx Holdings, Inc. (NASDAQ:GDRX - Free Report) by 16.7% in the 1st quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor owned 1,434,625 shares of the company's stock after acquiring an additional 205,789 shares during the quarter. Connor Clark & Lunn Investment Management Ltd. owned approximately 0.37% of GoodRx worth $6,327,000 at the end of the most recent reporting period.

Several other hedge funds also recently made changes to their positions in GDRX. Geode Capital Management LLC grew its stake in shares of GoodRx by 9.1% in the fourth quarter. Geode Capital Management LLC now owns 1,071,761 shares of the company's stock valued at $4,986,000 after buying an additional 89,032 shares in the last quarter. Barclays PLC grew its stake in shares of GoodRx by 18.4% in the fourth quarter. Barclays PLC now owns 165,928 shares of the company's stock valued at $772,000 after buying an additional 25,815 shares in the last quarter. Northern Trust Corp grew its stake in shares of GoodRx by 13.5% in the fourth quarter. Northern Trust Corp now owns 421,810 shares of the company's stock valued at $1,961,000 after buying an additional 50,256 shares in the last quarter. XTX Topco Ltd bought a new position in shares of GoodRx in the first quarter valued at $315,000. Finally, Russell Investments Group Ltd. bought a new position in GoodRx during the fourth quarter worth $314,000. 63.77% of the stock is owned by institutional investors.

GoodRx Stock Performance

Shares of GDRX traded up $0.19 during midday trading on Friday, reaching $3.73. 1,636,754 shares of the stock were exchanged, compared to its average volume of 1,655,840. GoodRx Holdings, Inc. has a twelve month low of $3.31 and a twelve month high of $8.80. The company has a quick ratio of 4.21, a current ratio of 4.21 and a debt-to-equity ratio of 0.75. The company has a market cap of $1.30 billion, a P/E ratio of 37.30, a PEG ratio of 1.49 and a beta of 1.24. The stock's 50 day simple moving average is $4.56 and its 200 day simple moving average is $4.51.

GoodRx (NASDAQ:GDRX - Get Free Report) last posted its quarterly earnings results on Wednesday, August 6th. The company reported $0.09 EPS for the quarter, missing analysts' consensus estimates of $0.10 by ($0.01). The company had revenue of $203.07 million during the quarter, compared to analyst estimates of $205.72 million. GoodRx had a net margin of 4.33% and a return on equity of 8.86%. The firm's revenue for the quarter was up 1.2% compared to the same quarter last year. During the same period last year, the firm earned $0.08 EPS. On average, sell-side analysts expect that GoodRx Holdings, Inc. will post 0.13 earnings per share for the current year.

Wall Street Analyst Weigh In

A number of research firms have commented on GDRX. UBS Group reduced their price objective on shares of GoodRx from $6.00 to $5.25 and set a "neutral" rating for the company in a research report on Tuesday, May 13th. Deutsche Bank Aktiengesellschaft reaffirmed a "hold" rating and set a $6.00 price objective on shares of GoodRx in a research report on Monday, August 11th. The Goldman Sachs Group reduced their price objective on shares of GoodRx from $6.00 to $5.00 and set a "neutral" rating for the company in a research report on Friday, May 9th. Raymond James Financial cut shares of GoodRx from a "strong-buy" rating to an "outperform" rating in a research report on Friday, August 8th. Finally, Wells Fargo & Company reduced their price objective on shares of GoodRx from $8.00 to $7.00 and set an "overweight" rating for the company in a research report on Tuesday, April 29th. Six analysts have rated the stock with a hold rating and six have issued a buy rating to the company's stock. According to MarketBeat.com, the stock presently has an average rating of "Moderate Buy" and an average price target of $6.18.

Insider Buying and Selling

In related news, major shareholder Equity Vii L.P. Spectrum sold 10,677 shares of the business's stock in a transaction dated Thursday, July 3rd. The stock was sold at an average price of $4.80, for a total value of $51,249.60. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available at the SEC website. 4.53% of the stock is currently owned by company insiders.

GoodRx Profile

GoodRx Holdings, Inc, together with its subsidiaries, offers information and tools that enable consumers to compare prices and save on their prescription drug purchases in the United States. The company operates a price comparison platform that provides consumers with curated, geographically relevant prescription pricing, and access to negotiated prices.